Fusion Antibodies Chief Executive Officer Adrian Kinkaid talked with Proactive at the latest One2One Investor Forum about the company’s recent progress and the development of its proprietary OptiMAL platform for antibody discovery.
Kinkaid explained that Fusion Antibodies is a pre-clinical contract research organisation specialising in antibody discovery, engineering, and supply. Discussing its technology, Kinkaid highlighted OptiMAL, a next-generation mammalian display platform capable of screening up to a billion antibody sequences at a time—far beyond the capabilities of competitors. He said: “The key to it all is antibodies—antibody, antibody, antibody. Our OptiMAL platform allows us to do a billion-scale screen, something no one else can currently achieve.”
The CEO also pointed to the company’s collaboration with the US National Cancer Institute, which validated the platform and plans to use it for multiple targets. Fusion Antibodies’ OptiMAL process is entirely animal-free, offering speed, scalability, and regulatory advantages. Kinkaid confirmed that the company plans a formal industry launch for OptiMAL at a major scientific conference in December, noting that client interest and pipeline opportunities are rising.
#FusionAntibodies #AdrianKinkaid #AntibodyDiscovery #BiotechInnovation #OptiMAL Platform #AIinBiotech #CancerResearch #LifeSciences #ContractResearch #ProactiveInvestors
